Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00471419
First received: May 7, 2007
Last updated: June 3, 2012
Last verified: March 2008

May 7, 2007
June 3, 2012
July 2006
August 2007   (final data collection date for primary outcome measure)
Corneal staining; dry eye sympton [ Time Frame: Immediate ]
Same as current
Complete list of historical versions of study NCT00471419 on ClinicalTrials.gov Archive Site
Corneal staining; dry eye sympton [ Time Frame: Prolonged ]
Same as current
Not Provided
Not Provided
 
Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye
Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Dry Eye
Drug: Rimexolone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
750
August 2007
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • documented dry eye history
  • ocular symptoms
  • tear use
  • dry eye ocular signs

Exclusion Criteria:

  • Under 18
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00471419
C-05-31
Not Provided
Not Provided
Alcon Research
Not Provided
Study Director: Michael Brubaker, PhD Alcon Research
Alcon Research
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP